Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRF1 | P14222 | 2/20 | 0.42 |
| ▸ | CAMK2D | Q13557 | 10/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.34 |
| ▸ | CSNK2B | P67870 | 2/20 | 0.34 |
| ▸ | NTRK1 | P04629 | 5/20 | 0.32 |
| ▸ | JAK2 | O60674 | 4/20 | 0.32 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12979332 | 1.00 | PRF1 (0.42) | PRF1CAMK2DKCNH2CSNK2BNTRK1 | |
| SCHEMBL3483036 | 1.00 | PRF1 (0.42) | PRF1CAMK2DKCNH2CSNK2BNTRK1 | |
| SCHEMBL12979612 | 0.85 | DYRK1A (0.35) | CAMK2DCSNK2BNTRK1JAK2 | |
| SCHEMBL860754 | 0.85 | DYRK1A (0.35) | CAMK2DCSNK2BNTRK1JAK2 | |
| SCHEMBL860753 | 0.85 | DYRK1A (0.35) | CAMK2DCSNK2BNTRK1JAK2 | |
| SCHEMBL12979532 | 0.85 | SMN1; SMN2 (0.34) | CAMK2DKCNH2CSNK2BAKT3 | |
| SCHEMBL12979694 | 0.85 | SMN1; SMN2 (0.34) | CAMK2DKCNH2CSNK2BAKT3 | |
| SCHEMBL12979020 | 0.84 | CAMK2D (0.39) | CAMK2DKCNH2NTRK1JAK2AKT3 | |
| SCHEMBL14679098 | 0.82 | CAMK2D (0.34) | PRF1CAMK2DKCNH2NTRK1JAK2 | |
| SCHEMBL12584199 | 0.82 | CSNK2B (0.39) | PRF1CSNK2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367681-B2 | Pyrazolopyrimidines and related heterocycles as kinase inhibitors | CYLENE PHARMACEUTICALS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-8367681-B2 | Pyrazolopyrimidines and related heterocycles as kinase inhibitors | CYLENE PHARMACEUTICALS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-8367681-B2 | Pyrazolopyrimidines and related heterocycles as kinase inhibitors | CYLENE PHARMACEUTICALS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20100331314-A1 | PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS | SENHWA BIOSCIENCES, INC. (TW) | 2010-12-30 | — | — | US | disclosed |
| US-20100331314-A1 | PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS | SENHWA BIOSCIENCES, INC. (TW) | 2010-12-30 | — | — | US | disclosed |
| US-20100331314-A1 | PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS | SENHWA BIOSCIENCES, INC. (TW) | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331314-A1 | PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS | PIM1, PIM2, PIM3 | PRF1 2051/4885CAMK2D 258/4885KCNH2 959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.